Featured Research

from universities, journals, and other organizations

BRAF inhibitor treatment causes melanoma cells to shift how they produce energy

Date:
March 8, 2013
Source:
Massachusetts General Hospital
Summary:
BRAF-positive metastatic malignant melanomas develop resistance to treatment with drugs targeting the BRAF/MEK growth pathway through a major change in metabolism, new research shows. The findings suggest a strategy to improve the effectiveness of currently available targeted therapies.

A multi-institutional study has revealed that BRAF-positive metastatic malignant melanomas develop resistance to treatment with drugs targeting the BRAF/MEK growth pathway through a major change in metabolism. The findings, which will be published in Cancer Cell and have been released online, suggest a strategy to improve the effectiveness of currently available targeted therapies.

Related Articles


"We were surprised to find that melanoma cells treated with the BRAF inhibitor vemurafenib dramatically change the way they produce energy to stay alive," says David E. Fisher, MD, PhD, chief of Dermatology at Massachusetts General Hospital (MGH) and a co-corresponding author of the Cancer Cell paper. "While current BRAF inhibitor treatment is a major improvement -- shrinking tumors in most patients and extending survival for several months -- patients eventually relapse. So there is an ongoing need to improve both the magnitude and durability of these responses."

In about half the cases of malignant melanoma -- the most deadly form of skin cancer -- tumor growth is driven by mutations in the BRAF gene. Research by investigators at the MGH Cancer Center and elsewhere has shown that treatment with drugs that block BRAF activity temporarily halts tumor growth. Combining a BRAF inhibitor with a drug that targets MEK, another protein in the same growth pathway, strengthens and extends the antitumor response. The current study was designed to investigate how BRAF inhibition changes metabolic activity within melanoma cells and to find other possible treatment targets.

The most common way that cells convert glucose into energy is called oxidative phosphorylation and largely relies on the activity of the cellular structures called mitochondria. Many cancer cells use an alternative mechanism that produces the energy compound ATP without involving mitochondria. A series of experiments by the MGH team revealed that the elevated BRAF activity in BRAF-positive melanoma cells suppresses oxidative phosphorylation by reducing expression of a transcription factor called MITF. Suppressing production of MITF reduced levels of a protein called PGC1α that regulates the generation and function of mitochondria. But melanoma cells treated with a BRAF inhibitor showed elevated MITF activity, along with increased expression of oxidative phosphorylation genes and greater numbers of mitochondria. By switching to oxidative phosphorylation to supply the energy they need, the tumor cells increased their ability to survive in spite of BRAF inhibitor treatment.

"These findings suggest that combination treatment with mitochondrial inhibitors could improve the efficacy of BRAF inhibitors in malignant melanoma," says Fisher, the Wigglesworth Professor of Dermatology at Harvard Medical School. "Several small molecules that target mitochondrial metabolism have been identified by investigators here at the MGH and elsewhere, and laboratory investigations of specific combinations of BRAF inhibitors with mitochondrial antagonists are currently underway."

Rizwan Haq, MD, of the MGH Cancer Center and Department of Dermatology, is lead author of the Cancer Cell paper, and co-corresponding authors are Zolt Arany, MD, Beth Israel Deaconess Medical Center, and Hans Widlund, PhD, Brigham and Women's Hospital. Support for the study includes grant R01AR043369-16 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Cancer Institute grants R01CA163336 and P50CA093683, and grants from the Melanoma Research Alliance and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation.


Story Source:

The above story is based on materials provided by Massachusetts General Hospital. Note: Materials may be edited for content and length.


Journal Reference:

  1. Rizwan Haq, Jonathan Shoag, Pedro Andreu-Perez, Satoru Yokoyama, Hannah Edelman, GlennC. Rowe, DennieT. Frederick, AeronD. Hurley, Abhinav Nellore, AndrewL. Kung, JenniferA. Wargo, JunS. Song, DavidE. Fisher, Zolt Arany, HansR. Widlund. Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF. Cancer Cell, 2013; DOI: 10.1016/j.ccr.2013.02.003

Cite This Page:

Massachusetts General Hospital. "BRAF inhibitor treatment causes melanoma cells to shift how they produce energy." ScienceDaily. ScienceDaily, 8 March 2013. <www.sciencedaily.com/releases/2013/03/130308103416.htm>.
Massachusetts General Hospital. (2013, March 8). BRAF inhibitor treatment causes melanoma cells to shift how they produce energy. ScienceDaily. Retrieved March 2, 2015 from www.sciencedaily.com/releases/2013/03/130308103416.htm
Massachusetts General Hospital. "BRAF inhibitor treatment causes melanoma cells to shift how they produce energy." ScienceDaily. www.sciencedaily.com/releases/2013/03/130308103416.htm (accessed March 2, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, March 2, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Treadmill Test Can Predict Chance Of Death Within A Decade

Treadmill Test Can Predict Chance Of Death Within A Decade

Newsy (Mar. 2, 2015) Johns Hopkins researchers analyzed 58,000 heart stress tests to come up with a formula that predicts a person&apos;s chances of dying in the next decade. Video provided by Newsy
Powered by NewsLook.com
Going Gluten-Free Could Get You A Tax Break

Going Gluten-Free Could Get You A Tax Break

Newsy (Mar. 2, 2015) If a doctor advises you to remove gluten from your diet, you could get a tax deduction on the amount you spend on gluten-free foods. Video provided by Newsy
Powered by NewsLook.com
GlaxoSmithKline and Novartis Try Swapping Success

GlaxoSmithKline and Novartis Try Swapping Success

Reuters - Business Video Online (Mar. 2, 2015) GlaxoSmithKline and Novartis have completed a series of asset swaps worth more than $20 billion. As Grace Pascoe reports they say the deal will reshape both drugmakers. Video provided by Reuters
Powered by NewsLook.com
How Can West Africa Rebuild After Ebola?

How Can West Africa Rebuild After Ebola?

Reuters - Business Video Online (Mar. 2, 2015) How best to rebuild the three West African countries struggling with Ebola will be discussed in Brussels this week. As Hayley Platt reports Sierra Leone has the toughest job ahead - its once thriving economy has been ravaged by the disease. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins